TIDMONT
RNS Number : 3756A
Oxford Nanopore Technologies plc
22 January 2024
Oxford Nanopore Technologies plc
Expansion of leadership team
22 January 2024
Oxford Nanopore Technologies plc (LSE: ONT) ("Oxford Nanopore"
or the "Group"), the company delivering a new generation of
nanopore-based molecular sensing technology, today announces the
expansion of the leadership team to support the business in its
next phase of growth.
Following a comprehensive search process, Nick Keher has been
appointed as Chief Financial Officer ("CFO") and Director of Oxford
Nanopore, effective 22 January 2024. Nick will succeed Tim Cowper,
who moves into a new role as Chief Operating Officer ("COO") after
performing both the role of CFO and fulfilling most of the
responsibilities typically assigned to a COO for the past five
years.
Nick is an experienced life sciences CFO, having previously
served as CFO of Clinigen Group and Benevolent AI. Prior to his CFO
roles he gained extensive experience in the life sciences industry
serving as Managing Director and Head of the European healthcare
equity research team at Royal Bank of Canada (RBC) and before that
held roles at Investec and GSK after switching from practising
pharmacy. Nick comes to the role with significant experience of
financial leadership of complex, scientific businesses, and has a
deep understanding of capital markets. In his role as CFO, Nick
will have responsibility for the Group's finance function and
investor relations.
In his new role as COO, Tim Cowper will lead the development of
Oxford Nanopore's expanding international footprint and operations,
including day to day operational functions such as manufacturing,
tech transfer, IT, supply chain, global distribution, EHS and set
up and management of international facilities.
There will be a transition period to ensure a smooth handover
and the efficient completion of the Company's 2023 audit and full
year financial results. Going forward in his role as COO, Tim will
continue to work closely with the new CFO to drive operational
performance and margin enhancement.
Gordon Sanghera, Chief Executive Officer of Oxford Nanopore,
commented:
"We are delighted to welcome Nick as CFO. His experience and
expertise of public company financial leadership in an innovative
business environment will support our sustainable growth towards
profitability. With his scientific background, he also understands
the specific opportunities for life science companies. These
combine with a passion to deliver impact for all of our
stakeholders. I am excited to be working with Nick to drive value
creation in the coming years."
"I would also like to thank Tim for his leadership as CFO - for
not only building and managing our financial function through our
IPO process and driving our transition to a public company, but
also leading many aspects of our operations in recent years. As we
continue to scale the business and enhance our supply chain to meet
growing demand for our products, Tim's expertise will continue to
be a significant asset to the business, and I look forward to
continuing to work with him in his new role as COO"
Nick Keher, Chief Financial Officer of Oxford Nanopore,
commented:
" This is a great opportunity to join a global life sciences
company with a unique, best-in-class technology platform and an
ambitious vision for the future. I am delighted to be joining
Gordon and the team at such an exciting time in the company's
growth journey and I look forward to working together to deliver
the business strategy and to create long-term shareholder
value."
Tim Cowper, Chief Operating Officer of Oxford Nanopore,
commented:
"I am excited to be moving into this new COO role, which is
critical as we further develop our sophisticated operations to
support expanding customer demand. Now is a good time to enhance
our management team to build on the significant growth that we have
achieved over the last five years. Nick's diverse experience will
help enable us to scale Oxford Nanopore to reach new heights and I
look forward to working with him in this next stage of our
development."
During the past five years, Nick Keher has been a director of
Clinigen Group. There are no further disclosures required in
respect of this appointment pursuant to Listing Rule 9.6.13.
[ENDS]
For further information, please contact:
Oxford Nanopore Technologies plc
Investors: ir@nanoporetech.com
Media: media@nanoporetech.com
Teneo (communications adviser to the Company)
Tom Murray, Olivia Peters
+44 (0) 20 7353 4200
OxfordNanoporeTechnologies@teneo.com
Notes
Remuneration Arrangements
Nick Keher's remuneration arrangements have been set in
accordance with the Directors' Remuneration Policy detailed in the
FY22 Annual Report. Further details will be set out in the
Directors' Remuneration Report for FY23.
About Oxford Nanopore Technologies plc:
Oxford Nanopore Technologies' goal is to bring the widest
benefits to society through enabling the analysis of anything, by
anyone, anywhere. The company has developed a new generation of
nanopore-based sensing technology that is currently used for
real-time, high-performance, accessible, and scalable analysis of
DNA and RNA. The technology is used in more than 120 countries, to
understand the biology of humans, plants, animals, bacteria,
viruses and environments as well as to understand diseases such as
cancer. Oxford Nanopore's technology also has the potential to
provide broad, high impact, rapid insights in a number of areas
including healthcare, food and agriculture. Oxford Nanopore
Technologies products are intended for molecular biology
applications and are not intended for diagnostic purposes. For more
information please visit: www.nanoporetech.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAPPUGUGUPCPWG
(END) Dow Jones Newswires
January 22, 2024 02:00 ET (07:00 GMT)
Oxford Nanopore Technolo... (LSE:ONT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oxford Nanopore Technolo... (LSE:ONT)
Historical Stock Chart
From Apr 2023 to Apr 2024
